Companion Animal Infectious Disease Diagnostics Market: as tick-borne disease geographic range expands and CAPC-forecast heartworm prevalence growth sustains SNAP-format point-of-care demand, laboratory consolidation and the annual wellness visit testing cadence convert per-visit test volume into durable reagent annuities for IDEXX and Zoetis, so the 50-million-dog under-testing gap defines the largest single addressable expansion opportunity, and USDA validation requirements create the regulatory moat that protects incumbent test manufacturers from new entrant disruption.

The global companion animal infectious disease diagnostics market size was USD 2.18 Billion in 2025 and is expected to register a revenue CAGR of 7.6% during the forecast period. Market revenue growth is driven by factors such as expanding tick-borne disease geographic range documented in CAPC annual prevalence forecasts, sustained SNAP-format point-of-care platform dominance at veterinary clinic annual wellness examinations, and the large residual under-testing gap in the US dog population that represents an addressable volume expansion independent of any new geographic market entry. The first driving factor is the expanding geographic range of heartworm and tick-borne disease pathogens into previously lower-risk US regions. The Companion Animal Parasite Council released its 2024 Pet Parasite Forecasts in April 2024, confirming continued spread of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia species, and Anaplasma species throughout the United States, with heartworm risk expanding into North and South Dakota and Montana, regions where comprehensive vector-borne disease screening was not previously standard veterinary practice. The second driving factor is the structural dominance of SNAP-format antigen and antibody point-of-care testing at annual wellness examinations. IDEXX Laboratories confirmed across its 2024 quarterly earnings releases that CAG Diagnostics recurring revenue growth was supported by sustained gains across its SNAP infectious disease antigen and antibody test platform that anchors heartworm, tick-borne disease, and viral infectious disease screening at veterinary clinics, and Zoetis's Vetscan Flex 4 Rapid Test has documented international deployment across 135 veterinary practices in Rio de Janeiro state, Brazil. The third driving factor is the large residual under-testing population within established heartworm endemic zones. Published epidemiological research estimates that of more than 70 million dogs in the United States, only approximately 23 million heartworm antigen tests were performed annually, leaving an estimated 50 million dogs untested despite widespread availability of preventive medications and validated diagnostic testing infrastructure. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way annual wellness examination protocols embed infectious disease panel testing into a recurring clinical visit cadence, which compounds test volume as veterinary practices adopt multi-pathogen combined panels that replace sequential single-pathogen screens. Once a veterinary clinic adds a combined heartworm and 4Dx tick-borne disease SNAP panel to its standard annual wellness protocol, each annual visit generates a guaranteed per-dog test revenue event that requires no additional clinical decision-making and no separate patient recall, so the per-visit revenue compounds as multi-pathogen panel adoption expands across the installed clinic base. As a result, demand and revenue share are concentrating around the USDA-validated multi-pathogen panel platforms that hold the broadest combination test menus with documented sensitivity and specificity above the CAPC 90% threshold, and the forecast tilts toward these validated incumbents rather than single-pathogen entrants that lack CAPC prevalence mapping inclusion. For instance, in April 2024, the Companion Animal Parasite Council published its 2024 Pet Parasite Forecasts confirming sustained high-risk status across established geographic corridors for heartworm, Lyme, ehrlichiosis, and anaplasmosis, alongside newly elevated risk in northern Great Plains and upper Midwest states, which creates a clinical and commercial reason for veterinarians in those newly at-risk regions to adopt comprehensive vector-borne disease screening protocols representing one of more than a dozen new regional adoption opportunities the CAPC forecast cycle creates annually. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the annual Companion Animal Parasite Council Pet Parasite Forecast cycle, which translates emerging vector-borne disease epidemiology into clinical practice guidance that veterinarians in newly affected regions use as the evidence base for adding comprehensive infectious disease screening to their standard annual wellness protocols. The CAPC forecast works as a demand driver because veterinarians in regions newly classified as high-risk require clinical and liability justification for expanding their testing protocols, and the CAPC forecast provides that institutional endorsement, so a single new geographic risk classification by CAPC converts an entire region's veterinary practice base from non-screeners to screeners for that pathogen. The CAPC 2024 Pet Parasite Forecasts released in April 2024 confirmed continuing geographic spread of Dirofilaria immitis, Borrelia burgdorferi, Ehrlichia species, and Anaplasma species throughout the United States, specifically documenting increased likelihood of heartworm infection expanding into North and South Dakota and Montana, regions historically outside the parasite's established range, alongside sustained high-risk status across established Mississippi River corridor and Atlantic coast endemic zones. In April 2024, the CAPC publication also confirmed continuing risk corridor expansion for Lyme disease into the upper Midwest states that border established northeastern and Great Lakes endemic zones, reinforcing the multi-pathogen dimension of the geographic risk expansion trend that supports combined heartworm and 4Dx tick-borne disease panel adoption at a single clinical protocol update. The effect on the market is a recurring annual demand increment at IDEXX and Zoetis as each CAPC forecast cycle translates into new regional protocol changes, creating a structural link between public veterinary epidemiology surveillance and commercial point-of-care test volume that compounds geographically as risk zones broaden. These are some of the key factors driving revenue growth of the market.

The second driver is the international replication of the US SNAP-format point-of-care infectious disease testing model in markets with comparable or exceeding endemic disease burdens, driven by IDEXX and Zoetis's confirmed international revenue growth and supported by published epidemiological evidence that international companion animal infectious disease prevalence justifies the same testing protocols deployed in the United States. International platform transfer works as a sustained driver because the endemic disease burden exists in international markets independently of testing infrastructure penetration, so each new veterinary clinic that adopts IDEXX SNAP or Zoetis Vetscan Flex 4 testing represents a net volume addition to the global installed base rather than market share displacement from a competitor. IDEXX confirmed double-digit international CAG Diagnostics recurring revenue growth across its 2024 quarterly earnings, and published research evaluating heartworm and tick-borne disease seroprevalence in Rio de Janeiro state, Brazil, using the Zoetis Vetscan Flex 4 Rapid Test across 135 veterinary practices and 1,787 canine blood samples documented heartworm disease prevalence of 21.3%, while published molecular surveillance of 2,492 canine samples across 22 Chinese provinces found 49.6% of dogs positive for one or more viral pathogens. These are some of the key factors driving revenue growth of the market.

"The 21.3% heartworm prevalence in Rio de Janeiro and the 49.6% pathogen-positive rate across Chinese provinces document endemic disease burdens comparable to or exceeding US established endemic zones in markets where point-of-care testing infrastructure penetration remains substantially below North American levels. That gap between documented disease prevalence and testing penetration is the structural international expansion opportunity for IDEXX and Zoetis over the forecast period."

Clarivant Market Intelligence, 2025

The third driver is the structural growth of the companion animal population in Asia Pacific and Latin American markets, supported by rising urban pet ownership rates and expanding veterinary clinic infrastructure investment that creates the clinical setting prerequisite for infectious disease panel testing adoption. Population-driven market growth operates differently from protocol-change-driven growth because it expands the total addressable testing base without requiring any change in existing testing behaviour, so the volume increment compounds directly with pet population growth rates rather than requiring separate clinical protocol adoption events. China, Japan, and Australia represent the three largest national companion animal infectious disease diagnostics markets within Asia Pacific, and published molecular surveillance of Chinese canine viral disease across 22 provinces between 2018 and 2024 found 49.6% of tested dogs positive for one or more pathogens, confirming substantial endemic disease burden supporting expanded diagnostic test deployment as veterinary clinic density increases. The effect on the market is a structural tailwind that operates independently of CAPC forecast cycles or USDA validation barriers, expanding the total global addressable market for IDEXX SNAP and Zoetis Vetscan platforms as companion animal ownership medicalisation rates in Asia Pacific and Latin America converge toward North American standards over the forecast period. These are some of the key factors driving revenue growth of the market.

However, the companion animal infectious disease diagnostics market faces adoption constraints from the persistent testing penetration gap within the established US dog population and the USDA validation requirements that limit new entrant competitive disruption. The under-testing gap is the primary constraint, since published research estimates approximately 50 million of more than 70 million US dogs go untested for heartworm annually despite CAPC recommendations, widespread availability of preventive medications, and USDA-validated test availability at essentially every veterinary clinic in the country, so the revenue growth rate is constrained by veterinary recommendation behaviour and pet owner compliance rather than product or pricing limitations. USDA validation requirements compound this, because the Companion Animal Parasite Council's requirement for minimum 90% sensitivity and specificity thresholds with external USDA validation for inclusion in national prevalence mapping establishes a regulatory barrier that extends new product development timelines by three to five years and requires capital investment in large-scale multi-site clinical validation studies that smaller entrants cannot readily fund, so the effective competitive moat protecting IDEXX SNAP and Zoetis Vetscan Flex 4 is regulatory rather than purely technological. Heartworm antigen test sensitivity limitation is a third constraint, since validated antigen tests achieve the 90% CAPC threshold only when three or more adult female worms are present, meaning the test misses a clinically significant proportion of early or low-burden infections and cannot serve the earlier intervention opportunity that would expand the clinical utility of annual screening into more frequent seasonal testing protocols, limiting test frequency per dog per year. These factors substantially limit companion animal infectious disease diagnostics market growth over the forecast period.

Based on test type, the global companion animal infectious disease diagnostics market is segmented into antigen tests, antibody tests, and molecular and PCR confirmatory testing. Antigen testing holds the largest revenue share, because the combined heartworm antigen and tick-borne disease antibody SNAP 4Dx Plus panel anchors the annual wellness examination testing protocol at the majority of US veterinary clinics and has the strongest CAPC clinical endorsement and USDA validation documentation of any companion animal infectious disease test platform. Antibody tests deployed for tick-borne disease, FeLV, and FIV screening represent the second-established test type, sharing the SNAP platform hardware with heartworm antigen tests and benefiting from the same clinic visit cadence. Molecular and PCR confirmatory testing is expected to register a rapid revenue growth rate in the global companion animal infectious disease diagnostics market over the forecast period, driven by veterinary reference laboratory adoption of next-generation sequencing-based multi-pathogen vector-borne disease panels that provide species-level pathogen identification beyond the antibody-level seropositive results delivered by SNAP platform screening tests, with IDEXX and Antech reference laboratories expanding PCR-based confirmatory test menus.

Heartworm pathogen category is expected to account for a significantly large revenue share in the global companion animal infectious disease diagnostics market during the forecast period

Based on pathogen category, the global companion animal infectious disease diagnostics market is segmented into heartworm, tick-borne disease, viral, and feline-specific pathogens. Heartworm collectively holds the largest pathogen category revenue share, reflecting the single-pathogen annual screening mandate embedded in CAPC clinical guidelines and the high USDA-validated antigen test performance that has made annual heartworm antigen testing the foundational infectious disease screening event in the US veterinary wellness calendar for more than two decades. Tick-borne disease is expected to register the fastest revenue growth rate in the global companion animal infectious disease diagnostics market over the forecast period, driven by CAPC-documented continuing geographic expansion of Lyme disease, ehrlichiosis, and anaplasmosis into previously lower-risk US regions, combined with the multi-pathogen 4Dx Plus panel architecture that captures Borrelia, Ehrlichia, and Anaplasma antibodies in a single point-of-care test alongside heartworm antigen, so each newly at-risk region adoption event translates into tick-borne disease test volume alongside the heartworm antigen volume increment.

Based on end-use, the global companion animal infectious disease diagnostics market is segmented into veterinary clinics and hospitals, reference laboratories, and shelter and rescue organisations. Veterinary clinics and hospitals hold the largest revenue share, reflecting the standard clinical practice of annual wellness examination point-of-care heartworm and tick-borne disease screening performed at the time and location of the pet visit, generating immediate per-visit test revenue without requiring reference laboratory turnaround time or follow-up appointment scheduling. The persistent under-testing gap, with published research estimating approximately 50 million of more than 70 million US dogs untested for heartworm annually, represents the largest unrealised addressable market opportunity within this end-use segment, as veterinary clinics serving this untested population represent a volume expansion opportunity for IDEXX and Zoetis independent of any new geographic market entry or product innovation. Reference diagnostic laboratories are expected to register the fastest revenue growth rate in this end-use segment, driven by molecular PCR confirmatory testing demand from clinics with SNAP-positive tick-borne disease results requiring species-level pathogen identification for optimal treatment selection, with IDEXX and Antech expanding molecular confirmatory panel menus.

Based on regional analysis, the companion animal infectious disease diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the Companion Animal Parasite Council's comprehensive national heartworm and tick-borne disease prevalence surveillance infrastructure provides the clinical endorsement framework that embeds annual testing in veterinary wellness protocols, and because IDEXX Laboratories and Zoetis are both headquartered in the United States and have their deepest installed testing base and laboratory infrastructure in the North American veterinary clinic network. IDEXX confirmed that US CAG Diagnostics recurring revenue growth outpaced underlying same-store clinical visit growth throughout 2024, reflecting the structural depth of the North American companion animal infectious disease testing installed base even as underlying clinic visit volume has moderated from pandemic-era peaks. The estimated 50 million untested US dogs identified in published epidemiological research represents the largest single addressable expansion opportunity within the global companion animal infectious disease diagnostics market, and lies entirely within the North American region, making domestic testing penetration improvement the primary near-term growth lever for the market as a whole.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national companion animal infectious disease diagnostics markets within Europe, with tick-borne disease testing reflecting comparable vector-borne pathogen exposure patterns to the United States even as heartworm prevalence varies more substantially across European latitudes. Mars's September 2024 acquisition of SYNLAB Vet expanded European veterinary diagnostic capacity including infectious disease testing infrastructure. The ongoing Iran-US sanctions and associated Strait of Hormuz maritime disruption through 2026 affect specialty antibody and antigen reagent component supply chains for European point-of-care infectious disease test manufacturers, increasing procurement costs that contribute to European diagnostic test pricing pressure. The result is steady rather than rapid growth, shaped more by reagent cost inflation and established reimbursement structures than by the geographic risk expansion dynamics driving North American volume.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and Australia represent the three largest national companion animal infectious disease diagnostics markets within the region. Published molecular surveillance research investigating canine viral infectious diseases in China between 2018 and 2024 tested 2,492 samples from dogs across 22 provinces, finding that 49.6% of dogs tested positive for one or more pathogens, with canine parvovirus type 2 the most commonly detected at 30.6% prevalence, confirming substantial documented infectious disease burden that supports expanding companion animal diagnostic test adoption as veterinary infrastructure and pet ownership continue to grow, and leaves more room for growth than in North America or Europe where testing penetration is substantially more advanced.

The market in Latin America is expected to register a rapid revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national companion animal infectious disease diagnostics markets within the region. Published research evaluating heartworm and tick-borne disease seroprevalence in Rio de Janeiro state, Brazil, using the Zoetis Vetscan Flex 4 Rapid Test across 135 veterinary practices documented heartworm disease prevalence of 21.3%, establishing substantial endemic disease burden that supports continued point-of-care diagnostic test adoption at Brazil's expanding private veterinary clinic network. The indirect effects of Iran-US sanctions on international freight costs along South American trade lanes through 2026 are maintaining elevated import costs for point-of-care infectious disease test kits and assay components entering Brazilian and Mexican distribution networks, slowing adoption rates in secondary cities beyond the primary commercial veterinary clinic centres in Sao Paulo, Mexico City, and Monterrey.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. South Africa and the United Arab Emirates represent the primary commercial markets within the region, with growing companion animal ownership and veterinary clinic infrastructure investment supporting incremental point-of-care infectious disease testing adoption. South Africa is the most established market on the African continent for companion animal infectious disease diagnostics, with Onderstepoort Biological Products and private veterinary reference laboratory networks providing foundational diagnostic infrastructure, while the Gulf Cooperation Council states are still building the veterinary primary care clinic density that would drive routine annual wellness visit test volumes toward the levels needed to support dedicated companion animal infectious disease diagnostic product deployment.